Rotavirus VP7 G1 antigen (VP7) (VP7)

Rotavirus VP7 G1 antigen is a major structural glycoprotein located on the outer capsid of Rotavirus A, specifically belonging to the G1 serotype which is the most prevalent cause of human rotavirus infections worldwide (UniProt P04502). This protein plays a critical role in the viral life cycle by mediating calcium-dependent stabilization of the triple-layered particle and facilitating the attachment and entry of the virus into host intestinal enterocytes (PubMed: 15507654). As a primary target for the host immune system, VP7 contains several neutralization epitopes that are essential for the development of protective immunity (PubMed: 11831706). Consequently, it serves as a key component in both monovalent and multivalent live-attenuated vaccines, such as Rotarix and RotaTeq, which aim to elicit serotype-specific and cross-reactive antibody responses (CDC, 2023). Therapeutic strategies focusing on VP7 involve the induction of neutralizing antibodies that prevent the virus from infecting cells, thereby reducing the severity of rotavirus-induced gastroenteritis (WHO, 2021). Monitoring the genetic diversity of the VP7 gene is crucial for assessing vaccine efficacy and detecting the emergence of new strains that might bypass existing immunity (PubMed: 22435231).

Other names

Outer capsid glycoprotein VP7G1-type VP7Major neutralization antigen VP7Glycoprotein VP7

Induction of neutralizing antibodies that target the VP7 glycoprotein to prevent viral attachment and entry into host cells (PubMed: 11831706).